Budget Impact Analysis of the Change in Peritoneal Dialysis Use Rate in Korea

2019 ◽  
Vol 39 (6) ◽  
pp. 547-552
Author(s):  
Jimin Kim ◽  
Na Rae Lee ◽  
Soo Kyung Son ◽  
Jung Pyo Lee ◽  
Jung Tak Park ◽  
...  

Background While the number of peritoneal dialysis (PD) patients has decreased by 14.4% from 2006 to 2016, the number of hemodialysis (HD) patients has sharply increased, by 237.2%, in the same period, leading to an increase in the total medical cost. We analyzed the effects of the changes in PD use rates for dialysis patients in Korea on the healthcare budget using budget impact analysis (BIA). Methods The analysis modeled the influence of the increase in dialysis for the target population, changes in modality use rate, and/or changes in costs per patient-year on total medical cost for patients on dialysis, using the National Health Insurance Service (NHI) claims data. We developed 8 scenarios according to the changing PD use rate. Results In scenarios 1 – 4 (increase in PD patients by 6%, 13%, 20%, and 50% of non-diabetic prevalent HD patients under 65), 5-year budget savings ranged from $47 million to $394 million (0.9% – 7.3% of the end-stage renal disease [ESRD] budget). In scenarios 5 – 8 (increase in incident PD patients by 20%, 50%, 70%, and 100% of non-diabetic patients under 65), 5-year savings ranged from $25 million to $74 million (0.5% – 1.4% of the ESRD budget). In all scenarios, budget savings were higher as PD patients increased, showing a gradually growing trend. Conclusion In all scenarios from the payer's perspective, savings could be achieved through an increase in PD use. Selecting PD for ESRD patients without different expected clinical outcomes between HD and PD would be beneficial to the NHI budget.

2014 ◽  
Vol 17 (7) ◽  
pp. A811
Author(s):  
S. Bavanandan ◽  
G. Ahmad ◽  
A.H. Teo ◽  
L. Chen ◽  
F.X. Liu

2014 ◽  
Vol 17 (7) ◽  
pp. A743
Author(s):  
Metry ABS ◽  
ElSisi GHAE ◽  
Abou Rawash ◽  
R Eldesouky

2016 ◽  
Vol 9 ◽  
pp. 8-14 ◽  
Author(s):  
Sunita Bavanandan ◽  
Ghazali Ahmad ◽  
Ai-Hong Teo ◽  
Lilian Chen ◽  
Frank Xiaoqing Liu

2011 ◽  
Vol 14 (7) ◽  
pp. A246
Author(s):  
R. Busutil ◽  
N. Ferko ◽  
O. Espallardo ◽  
R. Saadi

Author(s):  
Tatiana Valerevna Boyarskaya ◽  
Elena Vladimirovna Derkach

The sodium-glucose co-transporter type 2 inhibitors (SGLT2i) used in the treatment of type 2 diabetes mellitus (DM) do not only affect the blood glucose level, but also help to reduce body weight and blood pressure. Recently ipragliflozin, the new drug from the SGLT2i group has appeared on the Russian market. The aim of this study was to analyze the budget impact of including ipragliflozin into the vital and essential drugs (VED) list for treatment of type 2 DM in adults. Material and methods. Budget impact analysis was performed in a mathematical model. The modeling period was 5 years. The target population included adult patients with type 2 DM eligible for glucose-lowering therapy with SGLT2i. The number of patients during the modeling period was calculated based on the information about SGLT2i public procurement and the data from the Federal Register of DM (FRDM). The cost of ipragliflozin was calculated on the basis of the price planned for state registration if the drugis included into the VED list (2.118 rubles for 30 tablets, 50 mg each); costs of dapagliflozin and empagliflozin were equal to the registered maximum selling prices plus VAT and the weighted average maximum wholesale allowance in the Russian Federation. The sensitivity analysis was performed to the variability of prices and target population size. Results. The estimated number of patients treated with SGLT2i was 14.052 in the 1-st year and 47.392 in the 5-th year. The calculated difference in the cost of SGLT2i over 5 years between the current and the expected practice (if ipragliflozin is included into the VED list) was –3.02 million rubles (cost reduction by 0.06%). For the first year, costs decreased by 0.1 million rubles, or 0.02%. Conclusion. The inclusion of ipragliflozin into the VED list leads to a reduction in costs within the budget of the State guarantee program for free provision of medical care to citizens.


Sign in / Sign up

Export Citation Format

Share Document